Last reviewed · How we verify
Ulipristal Oral Tablet
Ulipristal Oral Tablet, marketed by Ain Shams Maternity Hospital, is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing use. The primary risk is the potential increase in competition following the 2028 patent expiry, which could impact revenue and market share.
At a glance
| Generic name | Ulipristal Oral Tablet |
|---|---|
| Also known as | Ella |
| Sponsor | Ain Shams Maternity Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive (PHASE2)
- Levonorgestrel Intrauterine System For Emergency Contraception (NA)
- Ulipristal Acetate for Use in Early Pregnancy Loss (PHASE2)
- Esmya Versus Surgery Before IVF/ICSI
- Adenomyosis and Ulipristal Acetate (PHASE2)
- UA Versus UAE in Treatment of Fibroids (PHASE4)
- PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PHASE3)
- On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ulipristal Oral Tablet CI brief — competitive landscape report
- Ulipristal Oral Tablet updates RSS · CI watch RSS
- Ain Shams Maternity Hospital portfolio CI